Physician profile
Alice Chu
NPI 1962513366
$167,238.53
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,034 · 2020: $91.91 · 2021: $164K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Health Care Systems INC. | $164,112.40 | 2021 | |
| Amgen INC. | $797.64 | 2019 | |
| Genzyme Corporation | $547.23 | 2019-2020 | |
| Abbvie INC. | $278.04 | 2019 | |
| Janssen Biotech, INC. | $205.73 | 2019 | |
| Novartis Pharmaceuticals Corporation | $164.75 | 2019 | |
| Pfizer INC. | $161.06 | 2019 | |
| Sanofi-Aventis U.S. LLC | $128.59 | 2019 | |
| Mallinckrodt Enterprises LLC | $119.12 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $117.89 | 2019 | |
| Glaxosmithkline, LLC. | $114.42 | 2019 | |
| Lilly USA, LLC | $101.62 | 2019-2020 | |
| Horizon Therapeutics Plc | $99.18 | 2019 | |
| Ucb, INC. | $62.33 | 2019 | |
| Ferring Pharmaceuticals INC. | $59.73 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $48.14 | 2019 | |
| Radius Health, INC. | $42.72 | 2019 | |
| Genentech USA, INC. | $38.69 | 2019 | |
| Medexus Pharma, INC. | $24.91 | 2019 | |
| Sobi, INC | $14.34 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alice Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.